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Abstract. 
Mass drug administration (MDA) to interrupt malaria transmission requires the participation of entire communities. 
As part of a clinical trial in western Cambodia, four villages received MDA in 2015–2016. Before approaching 
study communities, a collaboration was established with the local health authorities, village leaders, and village 
malaria workers. Formative research guided the development of engagement strategies. In each village, a team of 
volunteers was formed to explain MDA to their neighbors and provide support during implementation. Public 
mobilization events featuring drama and music were used to introduce MDA. Villages comprised groups with 
different levels of understanding and interests; therefore, tailored multiple engagement strategies were required. The 
main challenges were explaining malaria transmission, managing perceptions of drug side effects, and reaching 
mobile populations. It was important that local leaders took a central role in community engagement. Coverage 
during each round of MDA averaged 84%, which met the target for the trial. 
The spread of drug-resistant parasites poses a serious threat to malaria control in Southeast 
Asia.1 In response, strategies to interrupt local malaria transmission, including mass drug 
administration (MDA), have been proposed.2 The success of this approach, currently under pilot 
across the region, depends upon high uptake in target communities.3,4 For past MDAs, this has 
been challenging5 because of misconceptions about drug regimens, inadequate explanations of 
the rationale for MDA, limited awareness of disease risk, and asymptomatic malaria.6 To 
overcome these challenges, a range of community engagement (CE) activities are undertaken 
alongside MDA.7 In the global health literature, CE has various definitions, for example, 
promoting ethical conduct of research, or “working collaboratively” with communities “to 
address issues affecting the well-being of those people.”8,9 In this article, we focus on CE as a 
range of activities with the primary aim of promoting MDA coverage. 
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Battambang Province, an area of unstable malaria transmission in western Cambodia, has 
seen a decline in clinical Plasmodium falciparum malaria over the past decade.10 Recently, P. 
falciparum parasites in the area have become resistant to artemisinins and partner drugs used in 
artemisinin combination therapy.11–14 Village malaria workers (VMWs), present in most villages, 
are trained to diagnose and treat clinical malaria. Asymptomatic malaria infections go untreated 
and contribute to transmission, and are associated with travel to forests and a history of clinical 
malaria.15–19 In neighboring Pailin Province, prevalence surveys (2013–2014) revealed a 
reservoir of asymptomatic malaria.20 
As part of a clinical trial, two villages received MDA in 2015 and two in 2016. MDA 
consisted of three, monthly rounds of treatment with dihydroartemisinin–piperaquine. 
Participants were followed over 1 year to observe clinical malaria and cross-sectional surveys 
were conducted quarterly to determine the prevalence of asymptomatic malaria. This article 
describes the process of developing and implementing a CE strategy for MDA, outcomes, 
challenges, and lessons learned. To this end, we sought the views of study staff from all levels: 
policy-makers, scientists, and field-workers. The first step entailed the field team compiling a 
summary of the process ofCE, describing the preparatory work, listing activities, and adding the 
lessons learned. Local staff (who are fluent in Khmer and well integrated with the population) 
made key contributions to this report. 
Before approaching study communities, a series of meetings with provincial and local health 
authorities, village leaders, and VMWs enabled the study team to understand local political and 
social structures. Guided by local collaborators, the team spent several months conducting 
prevalence surveys to identify submicroscopic malaria and communities that would be suitable 
for MDA.21 Formative research was conducted in 12 selected villages to guide the CE strategy. 
Village leaders were interviewed using a semi-structured guide and, following the framework 
approach,22 themes to prioritize for engagement activities were identified. This entailed 
developing a matrix of summarized data of each research theme per respondent. Respondents 
recommended involving all political groups, VMWs, and government/private health staff in 
activities. In addition, in light of villagers’ limited knowledge about malaria transmission, 
malaria and study-specific education was recommended. Preferred CE activities included video 
shows, quizzes with prizes, art and games, and musical concerts. 
In 2015, local volunteers, VMWs, and village leaders joined the study team to conduct CE 
activities and MDA. Before MDA, research staff meet with different groups, such as mothers, 
school children, forest workers, and monks (Table 1). In every village, the major mobilization 
activity was a public concert when health information was presented. These were very popular 
and well-attended. To keep people informed and address issues as they arose, meetings and other 
activities continued during the three rounds of MDA. After the final round of MDA, the CE team 
continued to make weekly village visits to provide information about malaria and receive 
feedback. Before MDA in 2016, the engagement strategies were reviewed and lessons learned 
from 2015. An excess of detail about the study had reportedly confused people and we worked 
with local leaders to simplify the messages. A drama-based event replaced the concert. This 
enabled local people to be involved as actors and communicate the scripted health education 
messages. In addition, health messages were given by the local health authorities known to the 
villagers instead of members of the research team. 
All four invited villages agreed to participate in the study. Events such as meetings were 
well-attended and village malaria teams and volunteers were actively involved. For example, 
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attendance for the drama performances ranged from 67% (350/522) to 86% (250/291). During 
each MDA round, coverage averaged 84%—exceeding the trial target. 
We encountered several challenges when designing and implementing MDA. The rationale 
for MDA is difficult to convey, particularly explaining 1) asymptomatic malaria; 2) that 
asymptomatic infections contribute to transmission; 3) that to remove these infections people 
need to take drugs when they feel ill; and 4) that everyone in the village needs to participate for 
MDA to work. Within villages, education levels varied widely, and we had to take this into 
account when framing the rationale for MDA and key messages and tailoring engagement 
strategies (Table 2). 
Concerns from communities and staff emerged before, during, and after MDA about 
perceived side effects of antimalarials. We gave directly observed treatment during MDA and 
then monitored participants actively for a week and passively for a month. Post-MDA, minor 
side effects such as dizziness, tiredness, and cold-like symptoms were reported in all sites. Local 
nurses and village volunteers visited participants to assist and reassure them as needed. Side 
effects were discussed directly in public meetings. Moreover, MDA was conducted as part of a 
clinical trial, and communities were generally unaware of medical research. 
Another challenge was reaching migrants and forest workers, who are a group at higher risk 
of malaria infection but are more difficult to engage with as they often move in and out of the 
villages. We held targeted meetings with these groups at times when they were not busy and 
provided MDA when they returned from travel if they were away during scheduled rounds of 
MDA. In one village, most people belonged to an ethnic minority, which meant the translation of 
messages into the local language. Their leader was bilingual and after being formally asked he 
joined the local MDA team to translate and successfully mobilized people from his community. 
We learned that understanding the concerns and attitudes of local communities and 
addressing them via various engagement activities are integral to the success of MDA. From our 
experience over 2 years, public events, such as concerts and drama, were important and ensured 
everybody received the same information at the same time. We realized that events needed to be 
entertaining to attract large audiences, which also built relationships and generated trust between 
the research team and communities. 
As challenges often arose over time, a process of ongoing contact through meetings and 
regular visits with families was important. This highlights that multiple complementary 
engagement strategies were required. Participating in the MDA depended also on people’s trust,  
and local leaders were able to advice on the language and methods to communicate the rationale 
as well as taking a leading role in community mobilization. 
MDA that takes place under non-trial “real-life” conditions will face additional challenges as 
it will need to be organized to a great extent by communities themselves, and probably with 
fewer resources. At scale, effective community mobilization and local ownership will be 
essential if MDA is to be successful and sustainable over several years. Engagement of the 
population will need to build upon existing local structures of community leaders, government 
health staff, and village health workers, and expand to include various other representatives of 
the local community such as women’s leaders and forest workers. Without a large outside team 
to organize MDAs, local villages will need to create their own teams to mobilize their 
communities and educate them about malaria transmission and the rationale for MDA, including 
visits and follow-up of every household to ensure people participate during each round. Local 
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capacity will need to be developed to empower and enable villagers to lead MDAs. Well-
designed education materials and support from local authorities and health workers will be 
needed, including training of village MDA teams to increase their health literacy, support them 
to organize drug administration days, and keep accurate records. Motivated local MDA teams, 
with appropriate support, would be well placed to understand the concerns of their own 
communities and plan how to implement MDA in a locally adapted way to reach all parts of their 
community. 
In Southeast Asia, mass antimalarial administration for malaria elimination may be targeted 
at villages with proven reservoirs of asymptomatic malaria rather than over wider areas, 
requiring the engagement of individual communities. In Cambodia, a pilot MDA achieved good 
coverage and this may be attributable to close collaboration with national and local authorities 
and a community-directed engagement strategy. 
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FIGURE 1. Participation in mass drug administration supervised by a village malaria worker and health center nurse 
with village leaders in the background. This figure appears in color at www.ajtmh.org. 
TABLE 1 
Engagement activities conducted before, during, and after mass antimalarial drug administration 
Activity Description Aim 
Leaders and influential 
people 
Meetings were held with village leaders and influential 
people to introduce the project and plans for the year, and to 
obtain agreement for the whole village to work together. 
Formal introduction of 
study, build 
relationships 
Village volunteers Volunteers were selected to cover a group of households 
within the village and were responsible for helping 
communicate with the community and also lead invitations 
and assist during survey days. 
Capacity building, 
mobilizing participants, 
identifying problems 
Involve village 
malaria workers 
In groups and one-to-one, explain objectives again and to 
conduct participant selection and invitation process. 
Ensure aims are 
understood, identify 
groups affected by 
malaria 
Outreach activities 
with forest goers and 
migrants 
Small meetings, visits to forest: teaching, health education, 
contacting them for surveys, encouraging participation in 
drug administration. Include migrants at risk of malaria who 
are professionals, such as soldiers and mine clearance teams. 
Build knowledge and 
education among high-
risk and hard-to-reach 
groups 
Outreach to local 
opinion formers 
Small group meetings with local political leaders, teachers, 
shopkeepers, private sector health-care providers, traditional 
healers. 
Build relationships, 
avoid organized 
opposition to MDA 
Outreach to monks Visit pagoda, arrange day for monks to come for blessings, 
and talk on communities working together and the 
importance of health. 
Collaborate with 
existing authorities, 
build relationships 
Outreach to 
women/mothers 
In small groups, teach, listen to, and address concerns about 
women or children taking medicine. Explain exclusion of 
pregnant and lactating women during MDA. 
Build relationship, 
solicit views on MDA 
Local school activities Outdoor games, coloring in games, and prizes. Involving 
children in public performances ensures the parents will 
attend the event. 
Fun activities, 
encourage participation, 
avoid fear 
Post-MDA follow-up Daily follow-up during drug administration to record and 
assist with any reports of real or perceived adverse events. 
To identify any adverse 
events, ensure 
participant safety, avoid 
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negative perceptions 
Community concert 
(2015) 
Band, quiz, prizes, invited speakers, household gift packs, 
and snacks (main mobilization event before MDA) 
Provide information 
about MDA, build 
friendship and trust 
Community theater 
and art workshops 
(2016) 
Video performance, drama workshops, singing competition, 
public drama performance (main mobilization event before 
MDA) 
Provide information 
about MDA, build 
friendship and trust 
Incentives Compensation was provided when individuals attended 
surveys or participated in MDA. For each event, participants 
received snacks and a reimbursement for their time of USD 
2.5. In 2016 (after the clinical trial ended), no compensation 
was provided as MDA was conducted house-to-house and 
participation rates remained constant. 
To reimburse time away 
from work and motivate 
continuous participation 
Complimentary health 
care 
A field clinic was conducted during each survey and round 
of MDA to provide free treatment to villagers. 
Supporting healthcare in 
the community 
Informed consent Participants were gathered to explain malaria, MDA, and 
blood collection, through group presentations, and 
information was given using handouts, pictures, photos, and 
videos. Following this, written consent was obtained on an 
individual basis. 
Clinical trial specific: 
provide information to 
support the consent 
process and obtain 
community approval 
Monitoring and 
evaluation 
Census of villages and major CE meetings: meeting with 
household heads and village leaders, review of population 
list, house-to-house follow-up, record keeping. 
Collect feedback to 
adapt the CE strategy 
CE = community engagement; MDA = mass drug administration. 
TABLE 2 
Key experiences and lessons for mass antimalarial drug administration 
Experience from MDA in the context of a clinical trial 
Positives: well-resourced, novelty factor, compensation in 2015, small number of villages. Negatives: blood 
collection, trial procedures such as consent forms, and study concepts such as research and randomization are 
hard to convey 
Messages 
Messages need to be simple and consistent. The messengers need to first understand key concepts themselves. 
Smaller group meetings can be used to train locals who will implement MDA, followed by larger events to 
demonstrate popular and official support. Multiple engagement and education activities are recommended to 
reach all groups. 
Explaining asymptomatic malaria and MDA 
“Malaria is a tiny parasite that lives in people and feeds on blood. Some people may have malaria but do not feel 
sick. Mosquitos biting these people can spread malaria to other people. There are safe and effective medicines to 
cure malaria. If everybody in the village takes medicine at the same time then there will be nobody in the village 
who can infect other people. We call this MDA and we think it can stop people getting malaria. By joining MDA 
people can protect themselves and their families. After MDA people may still be at risk of malaria and so it is 
important to keep using bed nets and protection from mosquitos and still visit the village malaria worker if people 
think they may have malaria.” 
Explaining the study medicine and side effects 
“During MDA everyone will take a medicine called DHA-P for 3 days, then again next month and the month 
afterwards (three rounds in total). We know this medicine to be safe and effective and it has been used by village 
malaria workers for many years. All medicines can have side effects in some people but not all people get side 
effects. Most side effects from taking DHA-P are minor and do not last long. We do not expect that you will feel 
unwell after taking DHA-P, but if you do then inform a member of the MDA team and a nurse can come to help.” 
Lessons for implementation 
Build on existing local resources, health services, and social structures and take sufficient time to prepare. 
Involve stakeholders in advance to build trust and understanding and overcome potential skepticism, fear, 
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rumormongering, or political and social divisions. Providing MDA at a central location and house-to-house MDA 
are both acceptable. Public events, public censuses, public meetings, and public drug administration all mobilize 
the community and generate confidence about MDA. Engagement is important not only before MDA, but also 
during and after MDA to deal quickly and calmly with any real or perceived health issues that occur following 
treatment. 
DHA-P = dihydroartemisinin–piperaquine; MDA = mass drug administration. 
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